Adalvo has finalized a licensing and supply agreement with Daiichi Sankyo in Brazil, marking a significant milestone for both companies.
This partnership aims to leverage Adalvo’s expertise in the central nervous system (CNS) market to improve the accessibility and quality of CNS therapies for patients by effectively navigating market entry complexities, ensuring timely product availability and regulatory compliance.
Adalvo’s proven track record in CNS treatments, combined with its agile supply chain and strong IP strategy, provides a competitive edge in a market with increasing demand for high-quality, differentiated therapies.
This agreement is part of Adalvo’s broader commitment to expanding access to differentiated neurology treatments, building on its growing CNS portfolio, which includes successfully launched products such as Dimethyl Fumarate, Teriflunomide, Lisdexamfetamine Hard Capsules and Oral Solution.
Partner up now!
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Daiichi Sankyo
Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan, is dedicated to the creation and provision of pharmaceutical products and services in 26 countries to meet diverse medical needs in both developed and developing markets.
Born from the merger of two major Japanese pharmaceutical companies, Daiichi Sankyo commenced its activities on September 25, 2005, in Japan and on September 15, 2006, in Brazil. The integration of "Daiichi" and "Sankyo" has endowed the company with a legacy of innovation and leadership.
With over 17,000 employees worldwide and more than 100 years of scientific expertise, the company is based on one of the most promising pipelines, operating in the fields of Cardiology, Oncology, and Frontier – innovative discoveries across a variety of mechanisms and diseases.
In Brazil, Daiichi Sankyo maintains a product line aimed at various medical specialities, such as cardiology, CNS, gastroenterology, orthopaedics, oncology, inflammation, and pain. These products are marketed in states across all Brazilian regions and also exported to Latin America. Additionally, Daiichi Sankyo seeks to expand its operations through new projects, partnerships, or product licenses.
Spreading its mission across all continents, Daiichi Sankyo makes pharmaceutical research and drug development a means to provide humanity with what is most valuable: the hope of a healthy life and a better quality of life.
Disclaimer: The decision may be subject to appeal. Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.